Graefes Arch Clin Exp Ophthalmol:口服烟酸对视网膜中央静脉阻塞的影响

2017-04-01 luowenbo MedSci原创

烟酸是一种治疗血脂异常的药物,副作用为可导致血管舒张。以前的实例中发现,慢性视网膜中央静脉阻塞(CRVO)和黄斑囊样水肿(CME)的患者在系统性服用烟酸治疗高胆固醇血症的同时,CRVO与CME也得到了改善。该研究是为了评估烟酸对CRVO与CRVO相关眼部并发症的作用。

烟酸是一种治疗血脂异常的药物,副作用为可导致血管舒张。以前的实例中发现,慢性视网膜中央静脉阻塞(CRVO)和黄斑囊样水肿(CME)的患者在系统性服用烟酸治疗高胆固醇血症的同时,CRVO与CME也得到了改善。该研究是为了评估烟酸对CRVO与CRVO相关眼部并发症的作用。

一项前瞻性、单中心、非随机、干预性试验用于研究烟酸对CRVO的作用。研究对50名患者的最佳矫正视力(BCVA)、黄斑中心视网膜厚度(CMT)和眼表并发症进行了一年以上的随访研究分析,同时8名患者作为对照组。

平均起始logMAR BCVA为0.915,经过3/6/12个月烟酸治疗后logMAR BCVA改善分别为0.745(P=0.12)、0.665(P=0.02)、0.658(P=0.03).平均起始CMT为678.9mum,经过3/6/12个月盐酸治疗后,CMT改善分别为478.1mum(P=0.001)、388.6mum(P<0.001)、317.4(P<0.001 ).对照组的平均起始logMAR BCVA为1.023,并在12个月后恶化至1.162(P=0.36),平均起始CMT为700.0mum,并在12个月后恶化至490.9mum(P=0.06)。接受烟酸治疗的5名患者(13.2%)和3名(37.5%)对照组患者需要进行全视网膜光凝治疗新生血管

这些研究结果表明,烟酸可能与CRVO患者的眼功能改善与眼解剖结构改善有关。烟酸是否在CRVO患者的玻璃体腔注射治疗中具有辅助疗效,仍然有待进一步研究验证。

原文出处:

Gaynon, Michael W, et al. Effect of oral niacin on central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol.2017VN.

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1696708, encodeId=ca5c1696e08b9, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Mar 08 20:00:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801537, encodeId=361a180153eec, content=<a href='/topic/show?id=89ac90e38c9' target=_blank style='color:#2F92EE;'>#视网膜中央静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90738, encryptionId=89ac90e38c9, topicName=视网膜中央静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Oct 12 06:00:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697434, encodeId=1927169e4348b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Mar 05 04:00:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269857, encodeId=954a126985e23, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Apr 02 15:00:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414817, encodeId=ce81141481e7a, content=<a href='/topic/show?id=683e6e12629' target=_blank style='color:#2F92EE;'>#烟酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67126, encryptionId=683e6e12629, topicName=烟酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c703090847, createdName=zblhy, createdTime=Sun Apr 02 15:00:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541180, encodeId=d1ac1541180f2, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sun Apr 02 15:00:00 CST 2017, time=2017-04-02, status=1, ipAttribution=)]
    2018-03-08 tomyang96
  2. [GetPortalCommentsPageByObjectIdResponse(id=1696708, encodeId=ca5c1696e08b9, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Mar 08 20:00:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801537, encodeId=361a180153eec, content=<a href='/topic/show?id=89ac90e38c9' target=_blank style='color:#2F92EE;'>#视网膜中央静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90738, encryptionId=89ac90e38c9, topicName=视网膜中央静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Oct 12 06:00:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697434, encodeId=1927169e4348b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Mar 05 04:00:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269857, encodeId=954a126985e23, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Apr 02 15:00:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414817, encodeId=ce81141481e7a, content=<a href='/topic/show?id=683e6e12629' target=_blank style='color:#2F92EE;'>#烟酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67126, encryptionId=683e6e12629, topicName=烟酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c703090847, createdName=zblhy, createdTime=Sun Apr 02 15:00:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541180, encodeId=d1ac1541180f2, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sun Apr 02 15:00:00 CST 2017, time=2017-04-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1696708, encodeId=ca5c1696e08b9, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Mar 08 20:00:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801537, encodeId=361a180153eec, content=<a href='/topic/show?id=89ac90e38c9' target=_blank style='color:#2F92EE;'>#视网膜中央静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90738, encryptionId=89ac90e38c9, topicName=视网膜中央静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Oct 12 06:00:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697434, encodeId=1927169e4348b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Mar 05 04:00:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269857, encodeId=954a126985e23, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Apr 02 15:00:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414817, encodeId=ce81141481e7a, content=<a href='/topic/show?id=683e6e12629' target=_blank style='color:#2F92EE;'>#烟酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67126, encryptionId=683e6e12629, topicName=烟酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c703090847, createdName=zblhy, createdTime=Sun Apr 02 15:00:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541180, encodeId=d1ac1541180f2, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sun Apr 02 15:00:00 CST 2017, time=2017-04-02, status=1, ipAttribution=)]
    2018-03-05 fusion
  4. [GetPortalCommentsPageByObjectIdResponse(id=1696708, encodeId=ca5c1696e08b9, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Mar 08 20:00:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801537, encodeId=361a180153eec, content=<a href='/topic/show?id=89ac90e38c9' target=_blank style='color:#2F92EE;'>#视网膜中央静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90738, encryptionId=89ac90e38c9, topicName=视网膜中央静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Oct 12 06:00:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697434, encodeId=1927169e4348b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Mar 05 04:00:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269857, encodeId=954a126985e23, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Apr 02 15:00:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414817, encodeId=ce81141481e7a, content=<a href='/topic/show?id=683e6e12629' target=_blank style='color:#2F92EE;'>#烟酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67126, encryptionId=683e6e12629, topicName=烟酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c703090847, createdName=zblhy, createdTime=Sun Apr 02 15:00:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541180, encodeId=d1ac1541180f2, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sun Apr 02 15:00:00 CST 2017, time=2017-04-02, status=1, ipAttribution=)]
    2017-04-02 zutt
  5. [GetPortalCommentsPageByObjectIdResponse(id=1696708, encodeId=ca5c1696e08b9, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Mar 08 20:00:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801537, encodeId=361a180153eec, content=<a href='/topic/show?id=89ac90e38c9' target=_blank style='color:#2F92EE;'>#视网膜中央静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90738, encryptionId=89ac90e38c9, topicName=视网膜中央静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Oct 12 06:00:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697434, encodeId=1927169e4348b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Mar 05 04:00:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269857, encodeId=954a126985e23, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Apr 02 15:00:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414817, encodeId=ce81141481e7a, content=<a href='/topic/show?id=683e6e12629' target=_blank style='color:#2F92EE;'>#烟酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67126, encryptionId=683e6e12629, topicName=烟酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c703090847, createdName=zblhy, createdTime=Sun Apr 02 15:00:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541180, encodeId=d1ac1541180f2, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sun Apr 02 15:00:00 CST 2017, time=2017-04-02, status=1, ipAttribution=)]
    2017-04-02 zblhy
  6. [GetPortalCommentsPageByObjectIdResponse(id=1696708, encodeId=ca5c1696e08b9, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Mar 08 20:00:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801537, encodeId=361a180153eec, content=<a href='/topic/show?id=89ac90e38c9' target=_blank style='color:#2F92EE;'>#视网膜中央静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90738, encryptionId=89ac90e38c9, topicName=视网膜中央静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Oct 12 06:00:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697434, encodeId=1927169e4348b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Mar 05 04:00:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269857, encodeId=954a126985e23, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Apr 02 15:00:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414817, encodeId=ce81141481e7a, content=<a href='/topic/show?id=683e6e12629' target=_blank style='color:#2F92EE;'>#烟酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67126, encryptionId=683e6e12629, topicName=烟酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c703090847, createdName=zblhy, createdTime=Sun Apr 02 15:00:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541180, encodeId=d1ac1541180f2, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sun Apr 02 15:00:00 CST 2017, time=2017-04-02, status=1, ipAttribution=)]